China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate1 ST. HELIER, Jersey & SHANGHAI–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company with a proprietary …

Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I

EF-19 data confirm the effectiveness and safety of Optune as monotherapy and further strengthen Optune’s clinical profile in recurrent GBM ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune for the treatment of recurrent GBM will be presented as a virtual poster at …

Novocure’s response to COVID-19

Important information for our patients, caregivers and providers As the global impacts of COVID-19 continue to evolve, Novocure is committed to our mission and to transparent communication of our response to our patients, caregivers and providers. Aggressive cancers do not slow because of this global pandemic, and we remain as focused as ever on delivering …

Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

SHANGHAI & ST. HELIER, Jersey–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called Tumor Treating Fields, today announced that the first patient has been enrolled in a phase 2 pilot clinical trial evaluating the safety …

Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology

STELLAR trial demonstrated a promising median overall survival of 18.2 months when the NovoTTF-100L™ System was added to standard chemotherapies for the treatment of malignant pleural mesothelioma NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that results from the STELLAR trial …

German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune’s Survival Benefit for Patients with Newly Diagnosed Glioblastoma

National reimbursement decision for Optune® in Germany anticipated in 2020 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published its rapid report concluding that, based on a review of Novocure’s EF-14 phase 3 pivotal trial, patients with newly diagnosed glioblastoma (GBM) lived …

FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma

NovoTTF-100L, a Tumor Treating Fields delivery system, is the first FDA-approved mesothelioma treatment in more than 15 years In the STELLAR trial, malignant pleural mesothelioma patients treated with Tumor Treating Fields plus platinum-based chemotherapy experienced a median overall survival of 18.2 months ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the U.S. Food …

Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced at AACR Annual Meeting 2019

ST. HELIER, Jersey–(BUSINESS WIRE)– The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta. The grants represent a joint effort between Novocure (NASDAQ: NVCR) and the AACR to promote and support innovative research on Tumor Treating Fields. …

Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer

INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer Ovarian cancer is the fifth leading cause of cancer death among women ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor …

Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019

A special symposium session, intended to highlight therapeutic advances, will focus on Tumor Treating Fields as a fourth modality in cancer treatment The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today 48 presentations on Tumor Treating Fields …